Ajanta Pharma has entered into an in-licensing agreement with Prollenium Medical Technologies of Canada and will have Exclusive Marketing Rights for Prollenium’s highly successful dermal filler ‘Revanesse’ in India.
Ajanta Pharma has entered into an in-licensing agreement with Prollenium Medical Technologies of Canada. Prollenium Technologies has vast experience in the medical aesthetic industry and is involved in developing new generation products for the aesthetic market. The company is dedicated to designing, manufacturing and distributing a full range of aesthetic products, implants and injectables. Announcing the tie-up, Mr. Yogesh Agrawal, Executive Director, Ajanta Pharma Limited, said that the launch of Revanesse is of great significance for Ajanta as the company strengthens its presence in the dermatology segment.
Revanesse helps replenish lost hyaluronic acid in the skin thus leaving it well hydrated, supple and full of life. It is a quick treatment for anyone seeking more youthful looking skin. It adds volume and smoothens out imperfections in the skin and also helps protect fragile areas of the skin from ageing. Revanesse is a prescription product and must be used under professional guidance and the effects last around 6-12 months.
The total dermatology market in India is valued at approximately Rs.1300 crores and lifestyle cosmeceutical products like ‘dermal’ fillers and anti-aging products are fast gaining in popularity.
Ajanta Pharma, which is ranked by IMS-ORG as one of the fastest growing pharmaceutical companies in India has a well established portfolio in dermatology, cardiology, and ophthalmology. The launch of Revanesse will strengthen the company’s portfolio in the aesthetic segment in India.